After abruptly pulling its marketing application, DBV may be left with peanuts in race against Aimmune
They say slow and steady wins the race. In the sprint to market the first peanut allergy treatment, hare DBV Technologies $DBVT has just fumbled, announcing on Wednesday that it had rescinded the marketing application for its peanut allergy patch, following discussions with FDA regulators who are seemingly unhappy with the state of manufacturing and quality control data submitted. Meanwhile, tortoise Aimmune $AIMT is now in pole position to leapfrog its rival to secure first-mover advantage in the so-far underserved market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.